{
  "meta": {
    "title": "15_Bacterial_Respiratory_Infections",
    "url": "https://brainandscalpel.vercel.app/15-bacterial-respiratory-infections-0712c3c5.html",
    "scrapedAt": "2025-11-30T12:26:53.218Z"
  },
  "questions": [
    {
      "text": "Which of the following is the most important factor in reduction of diphtheria cases?",
      "choices": [
        {
          "id": 1,
          "text": "Chemoprophylaxis"
        },
        {
          "id": 2,
          "text": "Improved standard of living"
        },
        {
          "id": 3,
          "text": "Vaccination"
        },
        {
          "id": 4,
          "text": "Increased surveillance rates"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Vaccination</strong> is the most important factor responsible for the <strong>reduction of diphtheria cases</strong> over the past decade.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8280",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true about pertussis?",
      "choices": [
        {
          "id": 1,
          "text": "Most of the infections are subclinical"
        },
        {
          "id": 2,
          "text": "Most infectious during incubation period"
        },
        {
          "id": 3,
          "text": "Secondary attack rate is 90 % in unimmunized individuals"
        },
        {
          "id": 4,
          "text": "Cerebellar ataxia is a common chronic complication"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> secondary attack rate</strong> in pertussis is about<strong> 90% </strong>in <strong>unimmunized</strong> individuals.</p>\n<p>The source of infection in pertussis is a case of pertussis. There is <strong>no </strong>evidence of <strong>subclinical infections.&nbsp;</strong>The patients are <strong>most infectious</strong> during the <strong>catarrhal stage.</strong></p>\n<p>The <strong>chief complications</strong> of pertussis are:</p>\n<ul>\n<li>Bronchopneumonia</li>\n<li>Bronchitis</li>\n<li>Bronchiectasis</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8281",
      "difficulty": "medium"
    },
    {
      "text": "Droplet precaution and isolation is to be done for all of the following conditions except:",
      "choices": [
        {
          "id": 1,
          "text": "Pertussis"
        },
        {
          "id": 2,
          "text": "Diptheria"
        },
        {
          "id": 3,
          "text": "Localized varicella zoster"
        },
        {
          "id": 4,
          "text": "Mycoplasma pneumonia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Droplet precaution and isolation is not done for localized varicella zoster, as it is only transmitted through direct contact.</p>\n<p>Varicella-zoster localized in the patient with an intact immune system with a lesion that can be contained/covered do not require droplet precaution. <strong>Disseminated varicella</strong> in any patient requires <strong>airborne</strong> and <strong>contact precautions.</strong></p>\n<p><strong>Diphtheria, pertussis, and mycoplasma </strong>are transmitted by droplets and hence <strong>require droplet precaution</strong> and isolation.</p>\n<p>Although patients are not contagious starting 48 hours after antibiotic therapy, droplet precautions are typically maintained until the completion of the antibiotic course and are culture-negative on two cultures taken 24 hours apart. Droplet precautions include the use of masks, gowns, gloves and protective eye gear when providing direct patient care.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7012",
      "difficulty": "medium"
    },
    {
      "text": "According to IMNCI, which of the following is a key clinical sign for pneumonia classification?",
      "choices": [
        {
          "id": 1,
          "text": "Nasal flaring"
        },
        {
          "id": 2,
          "text": "Wheezing"
        },
        {
          "id": 3,
          "text": "Cough"
        },
        {
          "id": 4,
          "text": "Fast breathing"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>According to the<strong> IMNCI, three </strong>key clinical <strong>signs</strong> are used to assess a sick child with suspected pneumonia:</p>\n<ul>\n<li><strong>Respiratory rate</strong> (RR):<strong> d</strong><strong>istinguishes</strong> children who have <strong>pneumonia</strong> from those who do not. Children are classified under pneumonia if: \n<ul>\n<li><strong>&gt; 50/min</strong> RR for infants 2 months to 12 months</li>\n<li><strong>&gt; 40/min</strong> RR for children 12 months to 5 years of age</li>\n</ul>\n</li>\n<li><strong>Lower chest wall indrawing</strong> indicates <strong>pneumonia</strong></li>\n<li><strong>Stridor </strong>indicates those with <strong>severe pneumonia</strong> requiring hospital<strong> admission.</strong></li>\n</ul>\n<p>The following image gives the <strong>IMNCI</strong> classification for cough/difficulty in breathing in children.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3e291034de6a436ba34b096ad206bf77x1280x711.PNG\" alt=\"Explanation Image\"><p><strong>Signs of severe pneumonia are :</strong></p>\n<ul>\n<li>Not able to drink</li>\n<li>Persistent vomiting</li>\n<li>Convulsions</li>\n<li>Lethargic or unconscious</li>\n<li>Stridor in a calm child</li>\n<li>Severe malnutrition</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8282",
      "difficulty": "easy"
    },
    {
      "text": "According to IMNCI, a 6-month-old child is said to have pneumonia if the child has fast breathing with a respiratory rate more than:",
      "choices": [
        {
          "id": 1,
          "text": "40"
        },
        {
          "id": 2,
          "text": "60"
        },
        {
          "id": 3,
          "text": "30"
        },
        {
          "id": 4,
          "text": "50"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Three</strong> key clinical signs are used to assess a sick child with cough or difficult breathing:</p>\n<ul>\n<li><strong>Respiratory rate</strong> (RR):<strong> d</strong><strong>istinguishes</strong> children who have <strong>pneumonia</strong> from those who do not. Children are classified as pneumonia if:&nbsp;\n<ul>\n<li><strong>&gt; 50/min</strong>&nbsp;RR for infants 2 months to 12 months</li>\n<li><strong>&gt; 40/min</strong>&nbsp;RR for children 12 months to 5 years of age</li>\n</ul>\n</li>\n<li><strong>Lower chest wall indrawing</strong>&nbsp;indicates <strong>severe</strong>&nbsp;<strong>pneumonia</strong></li>\n<li><strong>Stridor </strong>indicates those with <strong>severe pneumonia</strong>&nbsp;requiring hospital<strong> admission.</strong></li>\n</ul>\n<p>The following image gives the <strong>IMNCI</strong> classification for cough/difficulty in breathing in children.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/629eaeea3b5c4e64a6356dca16827622x1280x711.PNG\" alt=\"Explanation Image\"><p><strong>Signs of severe pneumonia are :</strong></p>\n<ul>\n<li>Not able to drink</li>\n<li>Persistent vomiting</li>\n<li>Convulsions</li>\n<li>Lethargic or unconscious</li>\n<li>Stridor in a calm child</li>\n<li>Severe malnutrition</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7561",
      "difficulty": "medium"
    },
    {
      "text": "A one-and-half-year-old child was brought to the hospital with a history of breathlessness, fever, cough, and cold. On examination, respiratory rate was 46/min, and there were no chest retractions. Which is the most appropriate management?",
      "choices": [
        {
          "id": 1,
          "text": "Give IV antibiotics and observe"
        },
        {
          "id": 2,
          "text": "Give IV antibiotics and refer to higher centre"
        },
        {
          "id": 3,
          "text": "Oral antibiotics, warn of danger signs, and send home"
        },
        {
          "id": 4,
          "text": "No need of treatment only home remedies"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>From the given clinical scenario, it can be easily inferred that the child has <strong>pneumonia</strong>. The treatment for pneumonia for a child between <strong>2 months and 5 years</strong> of age is&nbsp;<strong>oral amoxicillin</strong> and <strong>home care advice</strong>.</p>\n<p>The following image gives the&nbsp;<strong>IMNCI</strong>&nbsp;classification for cough/difficulty in breathing in children.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b23ea6e413f945dcbd85f451ae09e57fx1280x711.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9576",
      "difficulty": "easy"
    },
    {
      "text": "A polysaccharide vaccine against Streptococcus pneumoniae has 23 serotypes. In which of the following patients is this vaccine most beneficial?",
      "choices": [
        {
          "id": 1,
          "text": "A child < 2 years"
        },
        {
          "id": 2,
          "text": "A patient with sickle cell disease"
        },
        {
          "id": 3,
          "text": "A patient with cystic fibrosis"
        },
        {
          "id": 4,
          "text": "A patient with recurrent otitis media"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The&nbsp;polysaccharide vaccine against <em>Streptococcus pneumoniae</em> <strong>(PPSV-23)</strong> is most beneficial for patients with&nbsp;<strong>sickle cell disease.</strong></p>\n<p>S. pneumoniae is an encapsulated organism that is detected by the spleen and is removed. However, in <strong>sickle cell disease,</strong> the sickled cells block the vessels in the spleen which results in <strong>splenic infarction.&nbsp;</strong>This <strong>hyposplenism</strong> results in an increased risk of pneumococcal infection. Hence, pneumococcal vaccine (PPSV-23) is given to these patients as a <strong>prophylactic measure</strong>&nbsp;to reduce this risk.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0179",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following tests is used to determine the prevalence of TB infection?",
      "choices": [
        {
          "id": 1,
          "text": "Sputum examination"
        },
        {
          "id": 2,
          "text": "Mantoux test"
        },
        {
          "id": 3,
          "text": "CB-NAAT test"
        },
        {
          "id": 4,
          "text": "Chest X-ray"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Mantoux or tuberculin testing</strong> is used to detect the <strong>prevalence of TB infection</strong>.</p>\n<p>Infection of tuberculosis does not always lead to disease. In latent infections, the Mantoux test can be positive without any clinical symptoms. Therefore, the prevalence of <strong>TB infection</strong> is detected by the <strong>Mantoux</strong> test.</p>\n<p>However, the prevalence of <strong>TB disease</strong> is confirmed by a&nbsp;<strong>sputum smear.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8283",
      "difficulty": "medium"
    },
    {
      "text": "A 24-year-old patient has been given an intradermal injection of 0.1ml PPD (5 tuberculin units) over the forearm.   After 72 hrs, the site is examined as shown in the image below. What is the interpretation of the result obtained?",
      "choices": [
        {
          "id": 1,
          "text": "Tuberculin test negative, suggesting immunity from TB"
        },
        {
          "id": 2,
          "text": "Tuberculin test positive, suggesting an active infection"
        },
        {
          "id": 3,
          "text": "Tuberculin test negative, suggesting a recent or past infection"
        },
        {
          "id": 4,
          "text": "Tuberculin test positive, suggesting a recent or past infection"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The above image&nbsp;shows an <strong>induration</strong> of<strong> &gt;10 mm</strong> after 72 hrs of intradermal PPD injection suggesting a <strong>positive tuberculin</strong> <strong>test</strong>(TST),<strong>&nbsp;</strong>indicating <strong>recent</strong> or <strong>past infection.</strong>&nbsp;</p>\n<p>In TST, 0.1 ml of PPD (purified protein derivative) containing 5 TU (tuberculosis unit) is <strong>injected intradermally and induration is read after 48-72 hours.</strong> An induration of 10 mm or more is considered positive&nbsp;in patients from countries with a&nbsp;high prevalence of tuberculosis. Surrounding erythema is not considered.&nbsp;</p>\n<p>A positive tuberculin test indicates <strong>hypersensitivity</strong> to <strong>tuberculoprotein,</strong> denoting either&nbsp;<strong>latent infection</strong> with tubercle bacilli, or <strong>BCG immunization, </strong>or<strong> recent</strong> or<strong> past infection</strong> with or without clinical disease.&nbsp;</p>\n<p>False positives may be seen in infections with related mycobacteria and false negatives in miliary tuberculosis, severely immunosuppressed states, etc.&nbsp;</p><hr><h3>Related Pearl: Tuberculin reaction size & candidates for treatment of latent Mycobacterium tuberculosis infection</h3><table>\n<tbody>\n<tr>\n<td><strong>Risk Group</strong></td>\n<td><strong>Positive Tuberculin Reaction Size</strong></td>\n</tr>\n<tr>\n<td>HIV infected persons</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Recent contacts of a patient with TB</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Organ transplant recipients</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Persons with fibrotic lesions consistent with old TB on chest radiography</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Immunosuppressed persons</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Persons with high risk medical conditions (silicosis &amp; end stage renal disease)</td>\n<td>&ge;5 mm</td>\n</tr>\n<tr>\n<td>Injection drug users</td>\n<td>&ge;10 mm</td>\n</tr>\n<tr>\n<td>Mycobacteriology lab personnel</td>\n<td>&ge;10 mm</td>\n</tr>\n<tr>\n<td>Children &lt;5 years of age</td>\n<td>&ge;10 mm</td>\n</tr>\n<tr>\n<td>Recent immigrants from high prevalence countries</td>\n<td>\n<p>&ge;10 mm</p>\n</td>\n</tr>\n<tr>\n<td>Low-risk persons</td>\n<td>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&ge;15 mm</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><p>Tuberculin reactions are read at 48-72 hr as the transverse diameter of the <strong>induration, </strong>and&nbsp;the diameter of the<strong> erythema is NOT considered.&nbsp;</strong></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/2a2ea1d8206440f9b5b088b11bcc211e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5965",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most appropriate method to assess the incidence of tuberculosis in the community?",
      "choices": [
        {
          "id": 1,
          "text": "Identify all positives to tuberculin test"
        },
        {
          "id": 2,
          "text": "Sputum examination of symptomatic patients"
        },
        {
          "id": 3,
          "text": "Identify new converter to tuberculin test"
        },
        {
          "id": 4,
          "text": "Screen all under 5 years children with tuberculin test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><span>Identification of <strong>new converters </strong>to the tuberculin test is a marker of the&nbsp;<strong>incidence</strong> of <strong>tuberculosis</strong>.&nbsp;</span><span>Identification of <strong>all positives </strong>to the tuberculin test is a marker of the&nbsp;<strong>prevalence</strong> of <strong>tuberculosis</strong>.</span></p>\n<p><span><strong>Tuberculin conversion</strong> refers to the situation where an individual&rsquo;s tuberculin skin test (TST) results in changes from negative (0&ndash;4 mm diameter induration) to positive (equal to or &gt;10 mm diameter induration) within a 24-month period.&nbsp;</span><span><strong>TST conversion</strong> is considered<strong> presumptive evidence </strong>of<strong> acquired latent tuberculosis</strong> infection (LTBI) and potential risk for progression to active tuberculosis disease.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0979",
      "difficulty": "hard"
    },
    {
      "text": "Tuberculin testing is done at which anatomical site?",
      "choices": [
        {
          "id": 1,
          "text": "Dorsum of left arm"
        },
        {
          "id": 2,
          "text": "Dorsum of right arm"
        },
        {
          "id": 3,
          "text": "Ventral aspect of left forearm"
        },
        {
          "id": 4,
          "text": "Ventral aspect of right forearm"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Mantoux/ Tuberculin testing</strong> is carried out by injecting 1 TU of PPD in <strong>0.1 ml</strong> <strong>intradermally</strong> on the flexor <strong>(ventral) surface</strong> of the <strong>left forearm,</strong> midway between elbow and wrist.</p>\n<p>The result of the test is usually read after 48-96 hours, but <strong>reading</strong> it after <strong>72 hours</strong> is ideal.</p>\n<p>The<strong> </strong>horizontal transverse diameter of induration is measured, based on which the following diagnosis can be inferred:</p>\n<ul>\n<li><strong>&lt; 6 mm –</strong> <strong>Negative</strong></li>\n<li>6–9 mm – <strong>Doubtful</strong></li>\n<li><strong>≥ 10 mm –</strong> <strong>Positive </strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8286",
      "difficulty": "medium"
    },
    {
      "text": "The approach shown in the image is a part of which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Joint TB Monitoring Mission 2017"
        },
        {
          "id": 2,
          "text": "National Strategic Plan for TB, 2017 -2025"
        },
        {
          "id": 3,
          "text": "Standards of TB Care"
        },
        {
          "id": 4,
          "text": "National AIDS Control Organization"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Detect &ndash; Treat &ndash; Prevent &ndash; Build</strong> approach for eliminating TB in India is part of the <strong>National Strategic Plan for TB</strong> (2017-2025). The components of this approach are:</p>\n<ul>\n<li><strong>Detect -&nbsp;</strong>Early identification of<strong> presumptive TB cases</strong>, at the first point of care, be it private or public sectors, and <strong>prompt diagnosis</strong> using high sensitivity diagnostic tests.</li>\n<li><strong>Treat -&nbsp;</strong>Provide <strong>sustained, equitable access </strong>to&nbsp;high quality <strong>TB treatment</strong>, care and support services.</li>\n<li><strong>Prevent -&nbsp;</strong>Prevent the <strong>emergence of TB</strong> in susceptible populations.</li>\n<li><strong>Build -&nbsp;</strong>Undertake <strong>critical management </strong>reforms<strong>, </strong>restructuring of HR and financial norms, pathways for private sector participation, in order to<strong> improve efficiency, effectiveness.</strong></li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e93ff86cd8944b2d965098f524cbbb41.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8284",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is the most rapid diagnostic test for pulmonary TB?",
      "choices": [
        {
          "id": 1,
          "text": "Quantiferon TB gold plus"
        },
        {
          "id": 2,
          "text": "Sputum microscopy"
        },
        {
          "id": 3,
          "text": "Radiometric BACTEC method"
        },
        {
          "id": 4,
          "text": "CB-NAAT"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>most rapid</strong> diagnosis of pulmonary TB can be done by <strong>sputum microscopy,</strong> with results in <strong>30 minutes</strong>.</p>\n<p>It has the <strong>least sensitivity</strong> and <strong>specificity</strong>. Smears are stained by Ziel Neelson acid-fast stain.</p>\n<p><strong>CBNAAT </strong>gives&nbsp;results <strong>within 90 minutes.&nbsp;</strong>Cartridge-based nucleic acid amplification test is a Mycobacterium tuberculosis-specific automated, cartridge-based nucleic acid amplification assay, having fully integrated and automated amplification and detection using real-time PCR.</p>\n<p><strong>Quantiferon TB gold plus</strong>&nbsp;takes <strong>24 hours</strong> to give the result.<strong>&nbsp;</strong>The radiometric&nbsp;<strong>BACTEC</strong> method takes approximately<strong>&nbsp;2-3 weeks.&nbsp;</strong><strong>Sputum culture</strong> takes approximately <strong>2 to 8 weeks.</strong>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8285",
      "difficulty": "hard"
    },
    {
      "text": "BCG vaccine provides protection against which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Pulmonary TB"
        },
        {
          "id": 2,
          "text": "CNS and disseminated TB"
        },
        {
          "id": 3,
          "text": "Pulmonary and CNS TB"
        },
        {
          "id": 4,
          "text": "Pulmonary and skeletal TB"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>BCG</strong> vaccine provides protection against<strong> CNS and disseminated TB.</strong></p>\n<p>It does not prevent primary infection. More importantly, it does not prevent reactivation of latent pulmonary infection, the principal source of bacillary spread in the community. The impact of BCG vaccination on transmission of <em>mycobacterium tuberculosis</em> is therefore limited.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7006",
      "difficulty": "medium"
    },
    {
      "text": "What is the next step in management of a TB smear positive patient with no significant findings on a chest X ray?",
      "choices": [
        {
          "id": 1,
          "text": "Repeat sputum smear examination"
        },
        {
          "id": 2,
          "text": "Start ATT"
        },
        {
          "id": 3,
          "text": "Do CB-NAAT"
        },
        {
          "id": 4,
          "text": "Do sputum culture"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The next best step in a <strong>smear-positive</strong> patient with <strong>no findings</strong> on<strong> chest-xray</strong> is to perform a <strong>CB-NAAT</strong>. This patient is a microscopically confirmed case of tuberculosis (TB).</p>\n<p>According to the <strong>TB annual report</strong>, CBNAAT has been tried to be established in all centres. Ideally, <strong>drug sensitivity status </strong>via<strong> NAAT</strong> is to be done following a sputum smear <strong>before initiation of treatment</strong>. This helps in the early detection and treatment of <strong>drug-resistant TB</strong>. This has been integrated into the regular TB services to detect rifampicin resistance at the time of diagnosis. Depending on the <strong>sensitivity </strong>of the tubercle bacilli, <strong>appropriate ATT</strong> is started. </p>\n<p>If NAAT is not done and sputum is positive, patient is considered as Microbiologically positive with sensitivity status unknown. </p>\n<p> </p><hr><h3>Related Pearl: Diagnostic algorithm for Pulmonary TB – National Tuberculosis Elimination Programme (NTEP) 2020 Guidelines</h3><p>Any case of&nbsp;<strong>presumptive pulmonary TB</strong>&nbsp;should undergo <strong>sputum examination + chest X-ray + CB-NAAT</strong></p>\n<ul>\n<li>If sputum and chest X-ray normal:<strong> rule out TB and refer</strong></li>\n<li>If sputum is positive and CB NAAT is positive:<strong>&nbsp;microbiologically confirmed case of TB</strong></li>\n</ul>\n<p>The following protocol is used for <strong>CB-NAAT testing:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e8d17e5087654b588b4b519b350acb71x1280x2558.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8288",
      "difficulty": "medium"
    },
    {
      "text": "You are posted in a TB clinic. You need to start an intensive phase (HRZE 75/150/400/275) regimen for a patient weighing 70 kgs. How many tablets of the FDCs are to be taken by him on a daily basis?",
      "choices": [
        {
          "id": 1,
          "text": "2"
        },
        {
          "id": 2,
          "text": "3"
        },
        {
          "id": 3,
          "text": "4"
        },
        {
          "id": 4,
          "text": "5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>An adult weighing <strong>65-75kg</strong> needs to take <strong>5 tablets of FDC</strong>&nbsp;(fixed-dose combinations)<strong>&nbsp;</strong>containing HRZE&nbsp;75/150/400/275 in the intensive phase.<strong>&nbsp;</strong></p>\n<p>The new WHO guidelines suggest the number of FDC tablets to be taken daily according to <strong>five weight band</strong> categories.</p>\n<table>\n<tbody>\n<tr>\n<td rowspan=\"2\">Weight category</td>\n<td colspan=\"2\">Number of tablets (FDCs)</td>\n</tr>\n<tr>\n<td>\n<p>Intensive phase</p>\n<p>HRZE&nbsp;</p>\n<p>75/150/400/275</p>\n</td>\n<td>\n<p>Continuation phase</p>\n<p>HRE&nbsp;</p>\n<p>75/150/275</p>\n</td>\n</tr>\n<tr>\n<td>25-34 kg</td>\n<td>2</td>\n<td>2</td>\n</tr>\n<tr>\n<td>35-49 kg</td>\n<td>3</td>\n<td>3</td>\n</tr>\n<tr>\n<td>50-64 kg</td>\n<td>4</td>\n<td>4</td>\n</tr>\n<tr>\n<td>65-75 kg</td>\n<td>5</td>\n<td>5</td>\n</tr>\n<tr>\n<td>&gt;75 kg&nbsp;</td>\n<td>6</td>\n<td>6</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: A <strong>TB patient kit</strong> contains the <strong>full course</strong> of <strong>treatment</strong> for a <strong>single patient</strong> and thus assures the TB patient that his or her medications will be available throughout treatment. The kit provides health workers with a container that has all the required drugs in the necessary strengths and quantities. This helps limit confusion and wastage and makes it easier to monitor the regularity of treatment; avoiding stock-outs also helps to maintain patient confidence in the health system.</p><p>The NTEP reports a high prevalence of undernutrition in people in India with tuberculosis. An unchanged or decreased BMI at 2 months of treatment seems to be associated with a five-fold higher risk of tuberculosis mortality. Nutritional support, was associated with a significantly reduced hazard of death during treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0983",
      "difficulty": "hard"
    },
    {
      "text": "According to NTEP, how will you classify a TB patient who had taken antitubercular drugs for only 3 weeks in the past?",
      "choices": [
        {
          "id": 1,
          "text": "New case"
        },
        {
          "id": 2,
          "text": "Previously treated case"
        },
        {
          "id": 3,
          "text": "Treatment after loss to follow-up"
        },
        {
          "id": 4,
          "text": "Recurrent TB case"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Under <strong>NTEP</strong>, a <strong>new case</strong> is defined as a <strong>TB</strong> patient who had <strong>never taken</strong> ATT previously <strong>or taken ATT</strong> for <strong>&lt;1 month.</strong></p><hr><h3>Related Pearl: Classification of TB Patients Based on History of Treatment</h3><p><strong>New case</strong> is defined as a TB patient who had</p>\n<ul>\n<li><strong>Never taken</strong> ATT previously or</li>\n<li>Taken ATT for <strong>&lt; 1 month</strong></li>\n</ul>\n<p><strong>Previously treated Case :&nbsp;</strong>Patients who have <strong>received 1 month or more</strong> of Anti TB drugs in the past. These include:</p>\n<ol>\n<li><strong>Recurrent TB:&nbsp;</strong>A TB patient who <strong>had completed course of treatment</strong> <strong>/ declared cured</strong> and now presenting as microbiologically confirmed case</li>\n<li><strong>Treatment after failure:&nbsp;</strong>Patients who had been treated for TB and <strong>their treatment failed</strong> at the end of most recent course of treatment</li>\n<li><strong>Treatment after loss to follow up:&nbsp;</strong>A TB patient who had <strong>been treated &gt; 1 month on ATT</strong> and registered as l<strong>ost to follow up</strong> and now presenting as microbiologically confirmed case of TB</li>\n<li><strong>Other previously treated patients:&nbsp;</strong>Patients who had been previously treated but whose <strong>outcome is now unknown/undocumented</strong></li>\n</ol>\n<p><strong>Transferred in:&nbsp;</strong>A TB patient who has been received in a TB unit after having registered in another TB unit for treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8289",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the appropriate schedule for the treatment of multi-drug resistant tuberculosis?",
      "choices": [
        {
          "id": 1,
          "text": "6 drugs for 4-6 months followed by 4 drugs for 12 months"
        },
        {
          "id": 2,
          "text": "7 drugs for 4-6 months followed by 4 drugs for 5 months"
        },
        {
          "id": 3,
          "text": "4 drugs for 4 months followed by  6 drugs for 10-12 months"
        },
        {
          "id": 4,
          "text": "5 drugs for 6 months followed by 4 drugs for 12 months"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The appropriate schedule for the treatment of multi-drug resistant tuberculosis<strong> (MDR-TB)</strong> is <strong>7 drugs</strong> for<strong> 4-6 months </strong>followed by<strong> 4 drugs</strong> for<strong> 5 months.</strong></p>\n<p>Note: Pearl 1720 has been updated according to NTEP 2021 guidelines.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7007",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is not used in the management of a patient with MDR-TB under NTEP?",
      "choices": [
        {
          "id": 1,
          "text": "Levofloxacin"
        },
        {
          "id": 2,
          "text": "PAS"
        },
        {
          "id": 3,
          "text": "Ethionamide"
        },
        {
          "id": 4,
          "text": "Cycloserine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>PAS </strong>(para-aminosalicylic acid)<strong>&nbsp;</strong>is not included under the MDR-TB regimen.&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8290",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true regarding the duration for treatment of XDR TB?",
      "choices": [
        {
          "id": 1,
          "text": "Intensive phase is for 6 to 9 months"
        },
        {
          "id": 2,
          "text": "Continuation phase is for 12 months"
        },
        {
          "id": 3,
          "text": "Total duration is for 20 months"
        },
        {
          "id": 4,
          "text": "A combination of oral and injection drugs are used"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>All oral longer MDR-TB regimen</strong> is used for the treatment of <strong>XDR-TB</strong> patients for a duration of <strong>20 months</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n</tr>\n<tr>\n<td>All oral longer MDR TB regimen</td>\n<td>Bdq(6 months) Lfx Lzd Cfz Cs for 18-20 months</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p><p><span data-preserver-spaces=\"true\">The </span><strong><span data-preserver-spaces=\"true\">WHO</span></strong><span data-preserver-spaces=\"true\"> has recently updated a </span><strong><span data-preserver-spaces=\"true\">new definition</span></strong><span data-preserver-spaces=\"true\"> of </span><strong><span data-preserver-spaces=\"true\">pre-XDR-TB</span></strong><span data-preserver-spaces=\"true\">, which defines TB caused by M. tuberculosis strains that fulfil the definition of multidrug-resistant TB (MDR/RR-TB) &amp; also </span><strong><span data-preserver-spaces=\"true\">resistant to any fluoroquinolone</span></strong><span data-preserver-spaces=\"true\">.</span></p><p>World Tuberculosis (TB) Day on March 24, 2024, reaffirms the global commitment to ending TB, one of the deadliest diseases. With a rise in drug-resistant TB, the focus is on investment, implementing the latest WHO recommendations, adopting innovations, and engaging civil society organizations after the UN High-level Meeting on TB in September 2023. It's a call to action to renew efforts and work collectively towards ending TB for good.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8291",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a criteria for the bedaquiline conditional access programme under RNTCP?",
      "choices": [
        {
          "id": 1,
          "text": "Patient below 5 years can be included"
        },
        {
          "id": 2,
          "text": "Post menopausal females can be included"
        },
        {
          "id": 3,
          "text": "Patients with stable controlled arrhythmia can be included"
        },
        {
          "id": 4,
          "text": "Pregnant patients are excluded"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Patients under 5 years are excluded from the&nbsp;bedaquiline conditional access programme<strong>.</strong></p>\n<p>The <strong>criteria</strong> to be met under the <strong>bedaquiline conditional access programme</strong> are as follows:</p>\n<ul>\n<li>Children aged <strong>5&nbsp;</strong>to <strong>&lt;18 years</strong> of age and weighing at least 15 kg (in consultation with a paediatrician)</li>\n<li>Females on<strong>&nbsp;non-hormone-based</strong><strong>&nbsp;contraceptive</strong>&nbsp;or <strong>post-menopausal females</strong> can be included.</li>\n<li>Patients with <strong>controlled stable cardiac arrhythmia</strong> can be considered after cardiac consultation.</li>\n<li><strong>Pregnant</strong> women to be <strong>excluded</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8292",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements regarding TB is false?",
      "choices": [
        {
          "id": 1,
          "text": "The Index TB  guidelines are used for extra pulmonary TB."
        },
        {
          "id": 2,
          "text": "X-pert MTB/RIF assay is an adjunct for diagnosis of lymph node TB."
        },
        {
          "id": 3,
          "text": "Steroids may be used in patients with pleural TB without HIV for 4 weeks."
        },
        {
          "id": 4,
          "text": "Duration of ATT for TB meningitis is 9 months."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Steroids</strong> may be used in HIV-negative patients with <strong>TB meningitis and pericarditis</strong> for 4 weeks, but not for pleural TB.</p>\n<p>The <strong>Index TB</strong> guidelines for <strong>extrapulmonary TB</strong> are as follows:</p>\n<ul>\n<li>Duration of ATT in&nbsp;TB meningitis is for&nbsp;9 months and&nbsp;lymph node and abdominal TB is<strong>&nbsp;</strong>6 months.</li>\n<li>X-pert MTB/RIF assay may be used as an adjunct in the diagnosis of lymph node TB and TB meningitis.</li>\n<li><strong>Steroids</strong> may be used in HIV-negative patients with <strong>TB meningitis and pericarditis</strong> for 4 weeks.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5817",
      "difficulty": "medium"
    },
    {
      "text": "Where is the National Tuberculosis Institute located?",
      "choices": [
        {
          "id": 1,
          "text": "Mumbai"
        },
        {
          "id": 2,
          "text": "Bangalore"
        },
        {
          "id": 3,
          "text": "Delhi"
        },
        {
          "id": 4,
          "text": "Hyderabad"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>National Tuberculosis Institute is located in <strong>Bangalore.</strong></p>\n<p>Important<strong> national centers for tuberculosis</strong> in India:</p>\n<ul>\n<li>Tuberculosis Research Center: Chennai</li>\n<li>National Tuberculosis Institute: Bangalore</li>\n<li>National Institute of Tuberculosis and Respiratory Diseases: Delhi</li>\n<li>JALMA Institute for Leprosy and Other Mycobacterial Diseases: Agra.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0980",
      "difficulty": "medium"
    }
  ]
}